medigraphic.com

2016, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2016; 54 (3)

Usefulness of the oncogenetic molecular counselling in adults whith familial cancer

Valdespino-Gómez VM, Valdespino-Castillo VE

Language: Spanish
References: 34
Page: 364-374
PDF size: 328.23 Kb.


ABSTRACT

More than 200 cancer susceptibility syndromes (CSS) have been recognized through performing classic epidemiologic studies and genetic linkage analysis. In most CSSs clinical conditions of the patients have been identified as well as their hereditary patterns and the predisponent genes to cancer development. Cancer hereditary identification is a useful condition, since cancer family integrants may benefit of efficient strategies in early screening and in tumor prevention strategies; this consultation is performed by oncogenetic molecular medical consultants who must be scientifically competent for Human Genetics and Cancer molecular biology domains. The oncogenetic molecular consult of patients and family relatives of cancer predisposition families is a medical service in health programs of developed and developing countries; in our country this type of medical service needs to be organized and settled to be part of the integral oncology medical service. The oncogenetic molecular consultation is a structural process of assessment and communication of the associated integral problems of the cancer inherited susceptibility in familial cancer.


REFERENCES

  1. Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505:302-8.

  2. Berger AH, Pandolfi PP. Cancer susceptibility syndromes. En De Vita VT Jr, Lawrence TS, Rosenberg SA, editores. Cancer. Principles & Practice of Oncology. 9th ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2011. pp.161-72.

  3. Cascón AS. Bases genéticas de la susceptibilidad al cáncer. En Bandrés FM, Urioste MA, editores. Planteamientos básicos del cáncer hereditario: principales síndromes. Madrid: Fundación Tejerina/Instituto Roche; 2011. pp.15-26.

  4. Stadler ZK, Sharader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol. 2014;32:687-98.

  5. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359:2143-53.

  6. Urioste MA. Detección e identificación de síndromes de susceptibilidad al cáncer. En Bandrés FM, Urioste MA, editores. Planteamientos básicos del cáncer hereditario: principales síndromes. Madrid: Fundación Tejerina/Instituto Roche; 2011. pp. 27-46.

  7. Urioste MA. El cáncer familiar y hereditario. Unidad Clínica de Cáncer familiar. Centro Nacional de Investigaciones Oncológicas. Madrid, España. Disponible en https://www.cnio.es/es/programas/prog504a1.asp [Consultado en diciembre de 2014].

  8. Urioste MA. El consejo genético como herramienta para el manejo de las familias con susceptibilidad genética al cáncer. En Bandrés FM, Urioste MA, editores. Planteamientos básicos del cáncer hereditario: principales síndromes. Madrid: Fundación Tejerina/ Instituto Roche; 2011. pp. 47-62.

  9. Vidal SM. Cáncer de mama hereditario: identificación y elección de pacientes para estudio molecular de los genes BRCA. Cancerología. 2008;3:51-61.

  10. Vaca-Paniagua F, Alvarez-Gomez RM, Fragoso-Ontiveros V, Vidal-Millan S, Herrera LA, Cantu D, et al. Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer. PLoS ONE. 2012:7:e37432.

  11. Villareal-Garza C, Alvarez-Gomez RM, Perez-Plasencia C, Herrera LA, Herzog J, Castillo D, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer. 2015;121:372-8.

  12. Kucherlapati R. Biology of personalized cancer medicine. En De Vita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer. Principles & Practice of Oncology. 9th ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2011. pp. 141-8.

  13. Pilgrim SM, Pain SJ, Tischkowitz MD. Opportunities and challenges of next-generation DNA sequencing for breast units. Br J Surg. 2014;101:889-98.

  14. Siggens L, Ekwall K. Epigenetics, chromatin and genome organization: recent advances from the ENCODE project. J Int Med. 2014;276:201-14.

  15. Lynch HT, Lynch JF, Shaw TG. La historia del cáncer hereditario. En publicación de la Sociedad Española de Oncología Médica. Introducción al cáncer hereditario Madrid. SEOM; 2011. pp.21-68.

  16. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015 Jan;17(1):70-87. doi: 10.1038/ gim.2014.147. Epub 2014 Nov 13.

  17. Osorio AC. Síndromes más frecuentes: síndrome de mama-ovario hereditario. En Bandrés FM, Urioste MA, editores. Planteamientos básicos del cáncer hereditario: principales síndromes. Madrid: Fundación Tejerina/Instituto Roche; 2011. pp. 63-84.

  18. Hofstatter EW, Chung GG, Harris LH. Molecular biology of breast cancer. En De Vita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer. Principles & Practice of Oncology. 9th ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2011. pp. 1392-400.

  19. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int. 2013;2013:ID 7473318.

  20. Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond breast and ovarian cancers: PARP inhibitors for BCRA mutation-associated and BRCA-like solid tumors. Front Oncol. 2014;4:42. doi:10.3389.

  21. Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25:32-40.

  22. Evans DG, Graham J, O’Connell S, Arnold S, Fitzsimmons D. Familial breast cancer: summary of updated NICE guidance. BMJ. 2013. 2013;346:f3839.

  23. Evans DGR, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, et al. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 2014;16:442-7.

  24. Perea JG. Síndromes más frecuentes: síndrome de Lynch. Otros síndromes de cáncer colorrectal. En Bandrés FM, Urioste MA, editores. Planteamientos básicos del cáncer hereditario: principales síndromes. Madrid: Fundación Tejerina/Instituto Roche; 2011. p.85-116.

  25. Shivdasani RA. Molecular biology of colorectal cancer. En De Vita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer. Principles & Practice of Oncology. 9th ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2011. pp.1074-83.

  26. Dekker N, Hermens RPMG, Elwyn G, van der Weijden T, Nagengast FM, van Duijvendijk P, et al. Improving calculation, interpretation and communication of familial colorectal cancer risk: Protocol for randomized controlled trial. Impl Science. 2010:5:6. doi:10:1186

  27. Steinke V, Engel C, Buttner R, Schackert HK, Schmiegel WH, Propping P. Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch sindrome. Dtsch Arztebi Int. 2013;110:32-8.

  28. Esplin ED, Snyder MP. Genomic era diagnosis and management of hereditary and sporadic colon cancer. World J Clin Oncol. 2014;5:1036-47.

  29. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:doi:10.1186/1750.

  30. Samuel N, Villani A, Fernandez CV, Malkin D. Management of familial cancer: sequencing, surveillance and society. Nat Rev Clin Oncol. 2014;11:723-31.

  31. Oliva R, Ballesta F. Aspectos de la expresión fenotípica y patrones no clásicos de herencia monogénica. En Oliva R, Ballesta F, Oriola J, Claria J. Genética Médica. 3th ed. Barcelona: Publicacions/Edicions de la Universitat de Barcelona; 2004. pp. 85-94.

  32. Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC, et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. BJC. 2013;110:535-45.

  33. Lakdawalla A, Fisher J, Ronaghi M, Fan J-B. Cancer genome sequencing. En Gelmann EP, Sawyers CL, Rauscher FJ III. Molecular Oncology. Cambridge, UK: Cambridge University Press; 2014. pp. 1-9.

  34. Pilgrim SM, Pain SJ, Tischkowitz MD. Opportunities and challenges of next-generation DNA sequencing for breast units. Br J Surg. 2014;101:889-98.




2020     |     www.medigraphic.com